Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Ivesa (furmonertinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Allist, ArriVent

Drug class:

EGFR inhibitor

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

›

EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	furmonertinib Sensitive: B - Late Trials furmonertinib Sensitive : B	furmonertinib Sensitive: B - Late Trials furmonertinib Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	furmonertinib Sensitive: B - Late Trials furmonertinib Sensitive : B	furmonertinib Sensitive: B - Late Trials furmonertinib Sensitive : B
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	furmonertinib Sensitive: B - Late Trials furmonertinib Sensitive : B	furmonertinib Sensitive: B - Late Trials furmonertinib Sensitive : B
EGFR exon 20 insertion	Lung Non-Squamous Non-Small Cell Cancer	EGFR exon 20 insertion	Lung Non-Squamous Non-Small Cell Cancer	furmonertinib Sensitive: B - Late Trials furmonertinib Sensitive : B	furmonertinib Sensitive: B - Late Trials furmonertinib Sensitive : B
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	furmonertinib Sensitive: C2 – Inclusion Criteria furmonertinib Sensitive : C2	furmonertinib Sensitive: C2 – Inclusion Criteria furmonertinib Sensitive : C2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	furmonertinib Sensitive: C2 – Inclusion Criteria furmonertinib Sensitive : C2	furmonertinib Sensitive: C2 – Inclusion Criteria furmonertinib Sensitive : C2
EGFR exon 20 mutation	Non Small Cell Lung Cancer	EGFR exon 20 mutation	Non Small Cell Lung Cancer	furmonertinib Sensitive: C2 – Inclusion Criteria furmonertinib Sensitive : C2	furmonertinib Sensitive: C2 – Inclusion Criteria furmonertinib Sensitive : C2
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	icotinib + furmonertinib Sensitive: C2 – Inclusion Criteria icotinib + furmonertinib Sensitive : C2	icotinib + furmonertinib Sensitive: C2 – Inclusion Criteria icotinib + furmonertinib Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	icotinib + furmonertinib Sensitive: C2 – Inclusion Criteria icotinib + furmonertinib Sensitive : C2	icotinib + furmonertinib Sensitive: C2 – Inclusion Criteria icotinib + furmonertinib Sensitive : C2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	icotinib + furmonertinib Sensitive: C3 – Early Trials icotinib + furmonertinib Sensitive : C3	icotinib + furmonertinib Sensitive: C3 – Early Trials icotinib + furmonertinib Sensitive : C3
EGFR N771_P772insH	Non Small Cell Lung Cancer	EGFR N771_P772insH	Non Small Cell Lung Cancer	furmonertinib Sensitive: C4 – Case Studies furmonertinib Sensitive : C4	furmonertinib Sensitive: C4 – Case Studies furmonertinib Sensitive : C4
EGFR exon 20 insertion	Lung Adenocarcinoma	EGFR exon 20 insertion	Lung Adenocarcinoma	anlotinib + furmonertinib Sensitive: C4 – Case Studies anlotinib + furmonertinib Sensitive : C4	anlotinib + furmonertinib Sensitive: C4 – Case Studies anlotinib + furmonertinib Sensitive : C4
EGFR N771_P772insVal	Lung Adenocarcinoma	EGFR N771_P772insVal	Lung Adenocarcinoma	furmonertinib Sensitive: C4 – Case Studies furmonertinib Sensitive : C4	furmonertinib Sensitive: C4 – Case Studies furmonertinib Sensitive : C4
EGFR S768_D770dupSVD	Lung Adenocarcinoma	EGFR S768_D770dupSVD	Lung Adenocarcinoma	furmonertinib Sensitive: C4 – Case Studies furmonertinib Sensitive : C4	furmonertinib Sensitive: C4 – Case Studies furmonertinib Sensitive : C4